Close Menu

NEW YORK (GenomeWeb) – Veracyte said after the close of the market on Tuesday that it is planning a public offering of 5 million shares of its common stock.

The molecular diagnostics firm will also grant underwriters a 30-day option to purchase up to 750,000 additional shares.

Veracyte said it plans to use the net proceeds for working capital and other corporate purposes, and that it may also use some of the proceeds to acquire or invest in complementary businesses or technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.